ABSTRACT Review of histopathological and clinical data showed that 153 patients at one hospital developed a second primary lung cancer during 1980-6, 10% of all those with lung carcinoma. There were 64 synchronous tumours (interval less than one year) and 89 metachronous tumours (interval over one year). The average interval between metachronous tumours was 6-1 years. The criteria for diagnosing a second primary lung cancer were any of the following: (1) different histological type; (2) different lobe; (3) interval between the two tumours of at least three years. The incidence of second primary tumours increases with survival, and close follow up is required for their early detection.
Introduction Methods
The incidence of a second primary neoplasm varies considerably, according to the organ affected. In general, it is 1-7-3-9% when a different organ is affected,'2 but reaches 5% for primary tumours of the head and neck region in combination with primary lung tumours.3 Undoubtedly, the development of a second tumour is sometimes a coincidence, but on occasion the same aetiological agent may be responsible: cigarette smoking, for example, is related to carcinomas ofboth the larynx and the lung.3 Second primary tumours in the same organ are best recognised for the colon, breast, and ovary.4 Second primary carcinomas ofthe lung are also well recognised but are rare, the reported incidence being 1S6-3-0%. This compares with figures of up to 10% for a second primary carcinoma in the breast." In those surviving more than three years, however, the incidence of second primary lung carcinoma rises to 1025%.71-Unfortunately, the criteria used to define a second primary lung carcinoma are often imprecise, and despite the high prevalence of lung cancer few studies of second primary lung tumour have been published.
During 1980-6 1540 patients with primary carcinoma of the lung were seen at St Antonius Hospital. Of these, 153 had a second primary lung tumour. Some patients had had their first primary tumour diagnosed before the study period. Any of the following criteria were used to define a lung tumour as being a second primary tumour: (1) different histological type from that of the first tumour; (2) 76 patients with a second tumour were considered inoperable. Survival studies were restricted to the 77 patients who had both tumours treated by surgery and who could therefore be assessed by extensive mediastinal lymph node mapping'4 and evaluation of the surgical specimens (surgicopathological staging: pTNM). The expected survival ofthese patients was calculated with the aid of the product limit method (Kaplan Meier) and the Mantel-Cox statistic for testing the equality of the survival curves. '5 Finally, the patients' smoking habits were ascertained to determine whether stopping cigarette smoking increased the interval between the two tumours. Many of the second tumours (64 of 153) appeared within one year. This could be taken as evidence that they represented a recurrence of the first growth rather than a new primary tumour, but there are several arguments against this. Firstly, all the second tumours were related anatomically to a bronchus. Secondly, most (53 of 64) were situated in the contralateral lung, in the absence of mediastinal lymph node invasion. Thirdly, the absence of extrapulmonary metastases makes it less likely that the second growth was a metastasis. Although solitary metastases are well recognised, in the absence of mediastinal lymph node disease solitary pulmonary metastases are extremely rare-there were none in our own series of 126 consecutive necropsies on patients with lung cancer from 1986 to 1988 (Wagenaar and van Bodegom, unpublished observations). We believe therefore that these synchronous tumours are likely to be two primary lung tumours rather than a single primary tumour with a solitary lung metastasis.
In this study second primary lung cancers formed 10% ofall lung cancers seen (4-2% synchronous, 5-8% metachronous). This is higher than the figure of 1-6 to 3 per cent reported previously despite the fact that our criteria were stricter. If attention is confined to patients who survived three years after the first tumour the percentage of second primary lung cancer increases to 20%. These figures indicate the impor- Bodegom, Wagenaar, Corrin, Baak, Berkel, Vanderschueren tance of follow up of patients with lung cancer. This should lead to the early detection of a second primary lung cancer, and thus increase the chance that the patient will be suitable for surgery. It would appear advisable to supervise these patients in the strict manner suggested for patients treated for head and neck cancer, as these patients have the same 10% risk of developing a second primary cancer in the lung.2 It is clear that we underestimated the risk of a second primary lung cancer, because many of our patients (50 of 89) had stage 3 squamous cell cancer when their second tumour was identified.
Men formed 96% of the patients in the present study, a higher proportion than the 80% in previously published reports.6 90 The age at diagnosis of the first and second primary tumour, the mean interval between the two diagnoses, and the percentage of tumours ofthe same histological pattern are all similar to those reported previously."' Three patients with synchronous and six with metachronous second primary lung cancers had a small cell cancer; in all cases this was combined with a non-small cell cancer, though in only one surgically treated patient the small cell cancer came first. This patient had limited disease treated with chemotherapy, to be followed six years later by a curative resection for stage 1 squamous carcinoma. Tests for highly sensitive tumour markers for small cell cancer gave negative results; but bone metastases, reported as small cell cancer metastases, developed two years later.'"'8 The possibility that the small cell carcinoma bone metastases were dedifferentiated metastases of the squamous cell carcinoma does not appear to have been considered previously. The sequence of small cell carcinoma followed by an independent non-small carcinoma has been noted previously and has stimulated speculation that chemotherapy for small cell carcinoma may have an oncogenic action favouring the appearance of a new type of cancer. 7 1920 The high percentage of second primary lung cancers might be considered an argument for limited surgical procedures, but it seems more logical to us to consider each tumour on its merits and maximise the chance of a cure by treating each one aggressively if figure  2 shows that there was, as expected, a significantly better survival (30% died from relapse within two years) than with stage 3 resected double tumours (85% died from relapse within two years). The poor results obtained with surgery in stage 3 disease, suggest that this form oftreatment has no place in the management when the second tumour is so advanced.
Finally, in this study, discontinuing smoking did not extend the interval between the first and the second primary metachronous lung cancers, despite the fact that smoking is the most important factor causing lung cancer. The interval between the first and the second tumours (6-6 years) was probably too short for detecting an effect ofgiving up smoking, for the risk of lung cancer in ex-smokers approaches that of nonsmokers only 15 years after they have given up smoking.24
